Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
TiGenix: TiGenix introduces ChondroCelect to Spanish orthopedic market; Belgian biomedical company signs distribution agreement with Spanish leading orthopedic company, IQL
Ist Teil von
M2 Presswire, 2003, p.1
Ort / Verlag
Coventry: Normans Media Ltd
Erscheinungsjahr
2003
Link zum Volltext
Beschreibungen/Notizen
LEUVEN (BELGIUM) -- TiGenix, a Belgium based biomedical company, active in the field of regenerative medicine, has signed a distribution agreement with IQL, a leading Spanish orthopedic company and subsidiary of Biomet-Merck, for the introduction of its lead product ChondroCelect to the Spanish market. Gil Beyen, CEO TiGenix, says: "It is an opportunity for TiGenix to bring ChondroCelect to the Spanish orthopedic market through a leading orthopedic company like IQL." Spain will be the first country where ChondroCelect will be commercially accessible for the patient. Who is IQL? Industrias Quirrgicas de Levante, s.l. (IQL) is a Valencia (Spain) based company that has been manufacturing and marketing traumatology and orthopedic implants and surgical material for more than forty years. IQL forms part of the Biomet-Merck Group, this joint Venture is composed by Biomet Inc company, a well established US multinational based in Warsaw, Indiana ( today the 4th largest orthopaedic company in the world) and Merck KGaA , a German pharmaceutical company based at Darmstad for more than a century.